Schedule 13G ownership disclosure

Keros Therapeutics Inc

Security class unavailable · CUSIP: 492327101

Event date: 2020-04-08

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,428,071
Percent of class
7.1000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001104659-20-046925
Form type
SC 13G
Filer
Foresite Capital Fund IV, L.P.
CIK
CIK 1704131
Filed
Apr 15, 2020
Reporting period
Apr 08, 2020
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub